Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Patents
Fitch: Pfizer's Ratings Unaffected by generic Norvasc launch
April 11th, 2007
Fitch Ratings does not expect Mylan Laboratories Inc.'s (Mylan) market introduction of amlodipine besylate tablets (generic Norvasc) in the U.S. today to have a material impact of Pfizer's Inc. (NYSE:PFE) (Pfizer) credit profile. Mylan's generic product, which already received full approval from the FDA, has been launched due to a favorable legal outcome for Apotex Inc., effectively invalidating Norvasc's patent protection. The launch triggered the six-month exclusivity period granted to Mylan as the first generic manufacturer to file its abbreviated new drug application (ANDA) to the FDA. The brand name product was Pfizer's second top-selling drug,...
Source: Medical Patent Law Weekly (2007-04-11)
|
